The identification of novel candidate markers is a key challenge in the development of cancer therapies. This can be facilitated by putting accessible and automated approaches analysing the current wealth of 'omic'-scale data in the hands of researchers who are directly addressing biological questions. Data integration techniques and standardized, automated, high-throughput analyses are needed to manage the data available as well as to help narrow down the excessive number of target gene possibilities presented by modern databases and system-level resources. Here we present CancerMA, an online, integrated bioinformatic pipeline for automated identification of novel candidate cancer markers/targets; it operates by means of meta-analysing exp...
Abstract: A revolution is underway in the approach to studying the genetic basis of cancer. Massive ...
Most oncological microarray studies focus on molecular distinctions in different cancer entities. Re...
Cancer is one of the four major non-communicable diseases (NCD), responsible for similar to 14.6% of...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
The identification of cancer-restricted biomarkers is fundamental to the development of novel cancer...
The identification of cancer-restricted biomarkers is fundamental to the development of novel cancer...
The identification of cancer-restricted biomarkers is fundamental to the development of novel cancer...
The DNA microarray has revolutionized cancer research. Now, scientists can obtain a genome-wide pers...
DNA microarrays have been widely used to study gene expression in human cancer. The primary analyses...
DNA microarrays have been widely used to study gene expression in human cancer. The primary analyses...
AbstractDNA microarray technology has led to an explosion of oncogenomic analyses, generating a weal...
DNA microarray technology has led to an explosion of oncogenomic analyses, generating a wealth of da...
Most oncological microarray studies focus on molecular distinctions in different cancer entities. Re...
Abstract: A revolution is underway in the approach to studying the genetic basis of cancer. Massive ...
Most oncological microarray studies focus on molecular distinctions in different cancer entities. Re...
Cancer is one of the four major non-communicable diseases (NCD), responsible for similar to 14.6% of...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
The identification of cancer-restricted biomarkers is fundamental to the development of novel cancer...
The identification of cancer-restricted biomarkers is fundamental to the development of novel cancer...
The identification of cancer-restricted biomarkers is fundamental to the development of novel cancer...
The DNA microarray has revolutionized cancer research. Now, scientists can obtain a genome-wide pers...
DNA microarrays have been widely used to study gene expression in human cancer. The primary analyses...
DNA microarrays have been widely used to study gene expression in human cancer. The primary analyses...
AbstractDNA microarray technology has led to an explosion of oncogenomic analyses, generating a weal...
DNA microarray technology has led to an explosion of oncogenomic analyses, generating a wealth of da...
Most oncological microarray studies focus on molecular distinctions in different cancer entities. Re...
Abstract: A revolution is underway in the approach to studying the genetic basis of cancer. Massive ...
Most oncological microarray studies focus on molecular distinctions in different cancer entities. Re...
Cancer is one of the four major non-communicable diseases (NCD), responsible for similar to 14.6% of...